ArticleScientific reports2025
Brain AT1 and AT2 receptors and nitric oxide in baroreflex regulation of renal sympathetic activity in unanaesthetised rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Central Sympathetic Nerve Activation-Mediated Hypertension: Target Mechanisms and Multimodal Interventions-From Basic Research to Clinical Translation.International journal of molecular sciences · 2026Review
- Role of Exercise in Modulating the Brain-Heart Axis in Cardiovascular Diseases.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This study investigated the role of brain AT1 and AT2 receptors and the nitric oxide (NO) system in modulating renal sympathetic nerve activity (RSNA) baroreflex in unanaesthetised rats. Baroreflex gain curves (BRC) were generated following intracerebroventricular (I.C.V.) infusion of saline, Ang II, or Ang II combined with either losartan, PD123319 (AT2 antagonist), or L-NAME (NO synthase inhibitor). An AT2 agonist (CGP42112) was also infused I.C.V. with L-NAME. RSNA baroreflex sensitivity increased by 60% (P = 0.004) following losartan compared to saline (-4.8 ± 1.9 vs. -3.0 ± 0.9), but not after CGP42112. I.C.V. Ang II increased maximum gain by ~ 70% (P = 0.003) compared to saline (-5.0 ± 1.6 vs. -3.0 ± 0.9). This effect was reversed when Ang II was co-infused with PD123319 (-3.7 ± 1.1), but not losartan. I.C.V. CGP42112 increased the overall response range of the baroreflex but lowered the minimum level it could reach compared to saline (P = 0.03 - 0.02). The baroreflex effects of I.C.V. CGP42112 (P = 0.013), but not Ang II, were abolished when co-infused with L-NAME. These findings demonstrate an important facilitatory role for AT2 in baroreflex regulation of RSNA in unanaesthetised rats at basal brain levels of Ang II, a mechanism that is dependent on a functional NO system. By contrast, AT1 exerts an inhibitory effect on the baroreflex that is independent of NO. These observations suggest that targeting central AT2 receptors may represent a potential therapeutic strategy for conditions such as neurogenic hypertension, where impaired baroreflex function is present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.